Assessment of Host-targeted Nanobody Therapeutics

SOL #: HT942626QE003Sources Sought

Overview

Buyer

DEPT OF DEFENSE

Defense Health Agency (Dha)

DEFENSE HEALTH AGENCY

FORT DETRICK, MD, 21702, United States

Place of Performance

Frederick, MD

NAICS

Research and Development in the Physical (541715)

PSC

General Science And Technology R&D Services; General Science And Technology; Basic Research (AJ11)

Set Aside

No set aside specified

Original Source

https://sam.gov/opp/37a309976cd744b89e169bddc7ba06fb/view

Timeline

Posted

Jan 7, 2026

Last Updated

Jan 12, 2026

Response Deadline

Jan 21, 2026, 3:00 PM

Qualification Details

Fit reasons

NAICS alignment with historical contract wins in similar service areas.
Scope strongly matches core technical capabilities and delivery model.

Risks

Past performance thresholds may require one additional teaming partner.
Potential clarification needed on staffing minimums before bid/no-bid.

Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Numerous neurotropic viral families are considered high priority pathogens to the Department of War (DOW), but the therapeutic decelopment in stymied by the difficulty of trafficking into into the Central Nervous System (CNS). This is mediated primarily by blood-brain barrier (BBB) tight junctions that prevent large molecules entry into the parenchymal space. However, the CNS has significant physiologically needs in the form of energy, oxygen and other molecular components. See Statement of Objectives (SOO) for specific information.